Market research
ADIL Adial Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 16M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.29
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US00688A3041
- Market cap
- 16M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.29
About
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ADIL discussion.
5 years, 4 months ago
Adial Pharmaceuticals, Inc is currently in a long term uptrend where the price is trading 17.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Adial Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 68.5% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 49.1% to $-3M since the same quarter in the previous year.
Based on the above factors, Adial Pharmaceuticals, Inc gets an overall score of 2/5.